Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

Trial Details

NCT ID
NCT04502394
Phase
PHASE1 / PHASE2
Sponsor
Kartos Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • KRT-232
  • acalabrutinib
Locations (sample)
  • Goshen, Indiana, United States|41.58227,-85.83444
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Dallas, Texas, United States|32.78306,-96.80667
  • Adelaide, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible…
  • Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment
  • ECOG 0 to 2
  • Adequate hematologic, hepatic, and renal functions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →